FindTrial
Sign In

Comparison of two tapazole reduction regimens in Graves' disease: a randomized controlled clinical trial

Comparison of two tapazole reduction regimens in Graves' disease: a randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076624
Enrollment
Unknown
Registered
2023-10-13
Start date
2023-10-13
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves' Disease

Interventions

Upper half :On the basis of the original dose, reduce the dosage of Tabazol by 5mg directly
Lower half:Maintain the original dose and reduce it by 5mg when FT4<17.0pmol/L.

Sponsors

The Second Affiliated Hospital, Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Graves' Disease, using tapazole; 2. Tapazole >= 10 mg; 3. FT4 17.1-22.0.

Exclusion criteria

Exclusion criteria: 1. Other causes of hyperthyroidism; 2. History of cardiovascular disease, kidney disease, and liver disease.

Design outcomes

Primary

MeasureTime frame
FT3, FT4;TRAb;—

Countries

China

Contacts

Public ContactWangen Li

The Second Affiliated Hospital, Guangzhou Medical University

liwg660@126.com+86 135 0003 1715

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026